Vir Biotechnology Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript

Oct 18, 2022 / 05:30PM GMT
Patrick Trucchio - HC Wainwright - Analyst

Welcome back, everyone, to the 3rd Annual HC Wainwright HBV Conference. My name is Patrick Trucchio. I'm a Senior Biotech Analyst at HC Wainwright. It's my pleasure to introduce our next presenters.

We have Howard Horn, CFO; Carey Hwang, Senior VP of Clinical Research and Head of Chronic Infection; and Phil Pang, Chief Medical Officer of Vir Biotechnology, a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technology to treat and prevent serious infections disease.

So maybe we can start first with some background on Vir including the founding of the company, what makes its platform unique and differentiated in the area of infectious disease.

Phil Pang - Vir Biotechnology, Inc. - EVP, Chief Medical Officer & Interim Head of Research

Well, so Patrick, I think that's a great place to start, because I think that what we've seen over the last few years is that infectious diseases truly are one of the greatest threats to health, economic security, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot